Insulin and Carbohydrate Dysregulation

Gelato, Marie C.
April 2003
Clinical Infectious Diseases;4/2/2003 Supplement 2, Vol. 36, pS91
Academic Journal
Patients with human immunodeficiency virus receiving highly active antiretroviral therapy (HAART) may experience abnormal body composition changes as well as metabolic abnormalities, including dyslipidemia, increases in triglycerides, low high-density lipoprotein cholesterol levels, and abnormal carbohydrate metabolism, ranging from insulin resistance with and without glucose intolerance to frank diabetes. Whether the body composition changes (i.e., increased visceral adiposity and fat wasting in the peripheral tissues) are linked to abnormalities in carbohydrate metabolism is unclear. The use of HAART with and without therapy with protease inhibitors (PIs) is related to carbohydrate abnormalities and changes in body composition. Regimens that include PIs appear to have a higher incidence of insulin resistance (up to 90%) and diabetes mellitus (up to 40%). The etiology of these abnormalities is not well understood; what is known about insulin and carbohydrate dysregulation with HAART is discussed.


Related Articles

  • Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects A Pharmacokinetic-Pharmacodynamic Analysis. Susan L. Rosenkranz; Kevin E. Yarasheski; Michael F. Para; Richard C. Reichman; Gene D. Morse // Metabolic Syndrome & Related Disorders;Jun2007, Vol. 5 Issue 2, p163 

    BackgroundHIV-infected patients treated with antiretroviral medications (ARVs) develop undesirable changes in lipid and glucose metabolism that mimic the metabolic syndrome and may be proatherogenic. Antiretroviral drug levels and their interactions may contribute to these metabolic...

  • Growth hormone reduced HIV-related visceral fat.  // Endocrine Today;11/10/2008, Vol. 6 Issue 20, p10 

    The article discusses a study of the effectiveness of low-dose growth hormone (GH) in reducing visceral fat and truncal obesity related to HIV, which was published in the 2008 issue of the "Journal of the American Medical Association." It showed decreased visceral adipose tissue, trunk fat,...

  • Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Bennett, Matthew T.; Johns, Kevin W.; Bondy, Gregory P. // Lipids in Health & Disease;2007, Vol. 6, p15 

    To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid lowering therapy in patients with HIV dyslipidemia. Retrospective analysis of lipid parameters was conducted for 33 patients with HIV who had been prescribed ezetimibe 10 mg per day. Mean total cholesterol was...

  • Atorvastatin and rosuvastatin have most favourable impact on lipids of patients with HIV. Carter, Michael // HIV Australia;2009, Vol. 8 Issue 4, p49 

    The article reports that lipid levels of patients with the HIV virus have been lowered by atorvastatin and rosuvastatin. It notes that the two drugs lessened the total cholesterol, LDL-C, and triglycerides of the patients. It mentions that the long-term risk of serious illnesses can be increased...

  • Changes in CD4+ cell count, lipid profile and liver enzymes in HIV infection and AIDS patients. Pasupathi, Palanisamy; Bakthavathsalam, Govindaswamy; Saravanan, Ganesan; Devaraj, Ayyaswamy // Journal of Applied Biomedicine (De Gruyter Open);Sep2008, Vol. 6 Issue 3, p139 

    This study was designed to find the correlation between changes in CD4+ cell count, lipid profile and liver marker enzymes in HIV-infected and AIDS patients. The study population consisted of 150 subjects, age and sex-matched and divided into three groups [control subjects (n=50), HIV infected...

  • Modeling the Influence of APOC3, APOE, and TNF Polymorphisms on the Risk of Antiretroviral Therapy-Associated Lipid Disorders. Tarr, Philip E.; Taffé, Patrick; Bleiber, Gabriela; Furrer, Hansjakob; Rotger, Margalida; Martinez, Raquel; Hirschel, Bernard; Battegay, Manuel; Weber, Rainer; Vernazza, Pietro; Bernasconi, Enos; Darioli, Roger; Rickenbach, Martin; Ledergerber, Bruno; Telenti, Amalio // Journal of Infectious Diseases;5/1/2005, Vol. 191 Issue 9, p1419 

    Background. Single-nucleotide polymorphisms in genes involved in lipoprotein and adipocyte metabolism may explain why dyslipidemia and lipoatrophy occur in some but not all antiretroviral therapy (ART)-treated individuals. Methods. We evaluated the contribution of APOG3 -482C → T,...

  • HIV DIGEST.  // Guide;Jun2007, Vol. 27 Issue 6, p91 

    The article offers information on health and the human immunodeficiency virus (HIV). Merck has announced good results from its two phase three clinical trials of HIV drug, Isentress, formerly known as MK-0518. It also presents a question regarding medication for HIV and a research shows that...

  • Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV-Infected Patients with Undetectable Virus Load. Gil, Paloma; de Górgolas, Miguel; Estrada, Vicente; Arranz, Alberto; Rivas, Pablo; Yera, Carmen; Garcia, Rosa; Granizo, Juan J.; Fernández-Guerrero, Manuel // Clinical Infectious Diseases;10/1/2004, Vol. 39 Issue 7, p1024 

    Background. Simplified highly active antiretroviral therapy (HAART) regimens are becoming widely used, particularly as a result of the side effects of and difficult compliance with protease inhibitor (PI) therapy. However, the long-term efficacy of HAART has not been properly assessed. Methods....

  • Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids. Falasca, K.; Ucciferri, C.; Mancino, P.; Pizzigallo, E.; Calza, L.; Vecchiet, J. // International Journal of STD & AIDS;Aug2009, Vol. 20 Issue 8, p580 

    Compared with healthy controls, HIV patients already have abnormal lipoprotein concentrations before the initiation of highly active antiretroviral therapy (HAART), which worsen with the therapy. HAART-associated dyslipidaemia features fundamental proatherogenic changes such as increased plasma...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics